Diagnostic accuracy of the soluble Fms-like tyrosine kinase-1/placental growth factor ratio for preeclampsia: a meta-analysis based on 20 studies
- PMID: 25716670
- DOI: 10.1007/s00404-015-3671-8
Diagnostic accuracy of the soluble Fms-like tyrosine kinase-1/placental growth factor ratio for preeclampsia: a meta-analysis based on 20 studies
Abstract
Purpose: To investigate the accuracy of the soluble fms-like tyrosine kinase-1(sFlt-1)/placental growth factor (PlGF) ratio to predict preeclampsia (PE).
Methods: A search in the PubMed, Embase, and Cochrane Library was conducted for human studies without language restriction. We included the studies reported sufficient data to reconstruct the diagnostic 2 × 2 table of sFlt-1/PlGF with testing of PlGF and sFlt-1 in serum or plasma. Two reviewers independently screened the articles. Disagreements were resolved by a third reviewer. Unpublished data were requested from the authors of the study by email.
Results: Twenty studies with 28 groups of women with different gestational ages were included in our study. The pooled diagnostic sensitivity and specificity of sFlt-1/PlGF were 0.78 and 0.84 with the area under the SROC curve (AUC) of 0.88. In subgroup analyses, the diagnostic value of sFlt-1/PlGF for early-onset PE is highest with a pooled diagnostic odds ratio (DOR) of 241 and AUC of 0.98.
Conclusions: The accuracy of sFlt-1/PlGF ratio for screening PE was moderate and was high for early-onset PE. High-quality studies are needed to confirm their usefulness in prediction of PE in clinical practice.
Similar articles
-
[Value of second trimester maternal serum sFlt-1, PlGF and their ratio in the prediction of preeclampsia].Zhonghua Fu Chan Ke Za Zhi. 2014 Jan;49(1):22-5. Zhonghua Fu Chan Ke Za Zhi. 2014. PMID: 24694913 Chinese.
-
Onset threshold of the plasma levels of soluble fms-like tyrosine kinase 1/placental growth factor ratio for predicting the imminent onset of preeclampsia within 4 weeks after blood sampling at 19-31 weeks of gestation.Hypertens Res. 2013 Dec;36(12):1073-80. doi: 10.1038/hr.2013.95. Epub 2013 Aug 22. Hypertens Res. 2013. PMID: 23966056
-
Prediction of preeclampsia with angiogenic biomarkers. Results from the prospective Odense Child Cohort.Hypertens Pregnancy. 2016 Aug;35(3):405-19. doi: 10.3109/10641955.2016.1167219. Epub 2016 May 9. Hypertens Pregnancy. 2016. PMID: 27159383
-
Combining Biomarkers to Predict Pregnancy Complications and Redefine Preeclampsia: The Angiogenic-Placental Syndrome.Hypertension. 2020 Apr;75(4):918-926. doi: 10.1161/HYPERTENSIONAHA.119.13763. Epub 2020 Feb 17. Hypertension. 2020. PMID: 32063058 Free PMC article. Review.
-
Biomarkers and the Prediction of Adverse Outcomes in Preeclampsia: A Systematic Review and Meta-analysis.Obstet Gynecol. 2021 Jan 1;137(1):72-81. doi: 10.1097/AOG.0000000000004149. Obstet Gynecol. 2021. PMID: 33278298
Cited by
-
Comparative risks and predictors of preeclamptic pregnancy in the Eastern, Western and developing world.Biochem Pharmacol. 2020 Dec;182:114247. doi: 10.1016/j.bcp.2020.114247. Epub 2020 Sep 25. Biochem Pharmacol. 2020. PMID: 32986983 Free PMC article. Review.
-
Mechanisms of Endothelial Dysfunction in Hypertensive Pregnancy and Preeclampsia.Adv Pharmacol. 2016;77:361-431. doi: 10.1016/bs.apha.2016.04.008. Epub 2016 Jun 14. Adv Pharmacol. 2016. PMID: 27451103 Free PMC article.
-
Large-scale prospective serum metabolomic profiling reveals candidate predictive biomarkers for suspected preeclampsia patients.Sci Rep. 2025 Feb 9;15(1):4807. doi: 10.1038/s41598-025-87905-9. Sci Rep. 2025. PMID: 39922859 Free PMC article.
-
Pre-eclampsia.Nat Rev Dis Primers. 2023 Feb 16;9(1):8. doi: 10.1038/s41572-023-00417-6. Nat Rev Dis Primers. 2023. PMID: 36797292 Review.
-
An exploratory study into the role of miR-204-5p in pregnancy-induced hypertension.Exp Ther Med. 2017 May;13(5):1711-1718. doi: 10.3892/etm.2017.4212. Epub 2017 Mar 9. Exp Ther Med. 2017. PMID: 28565757 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous